THERAPEUTIC MODALITIES Archives - Page 3 of 24

R&D Strategies for T Cell Engager Drugs

From hematologic malignancies to solid tumors Introduction: Amid a surge of advancements in immunotherapy, T cell engager (TCE) therapy has...

Screening Strategies for Molecular Glue Discovery

Molecular glues are molecules that can encourage two proteins to interact when they otherwise may not. As a consequence, they...

Antibody-Targeted Precision Medicines

Antibody-targeted therapies—including antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), and degrader-antibody conjugates (DACs)—are reshaping precision medicine by enabling highly selective delivery...

Evolution of AAV Therapy: Challenges, Breakthroughs, and Future Directions

Overview of AAV Gene Therapy: Evolution and Current Landscape Adeno-associated virus (AAV) is a non-enveloped, replication-defective single-stranded DNA virus belonging...

Solving the Complexities of T Cell Engager Development

T-cell engagers (TCEs) are a class of bispecific antibodies that simultaneously bind tumor cells and T cells, activating T cells...

High-throughput FAMA Assay to Measure Humoral Immunity against Varicella-Zoster Virus

Varicella-zoster virus (VZV) is a highly contagious alpha-herpesvirus that infects more than 90% of people worldwide. The primary infection with...

Efficacy of a TL1A Antibody in an Acute Colitis Mouse Model

Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease, is a chronic, immune-mediated disorder characterized by persistent inflammation...

Navigating the ADC Development Pathway

Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics, but their complex structure poses significant development and safety challenges....

Evaluations of Targeted Delivery Systems for RNA Therapeutics

RNA therapeutics can target specific mRNAs with high specificity, making them advantageous for treating genetic diseases caused by known mutations....

Knowledge Library